LAG3 and B-cell chronic lymphocytic leukemia: In this line, treatment with relatlimab, a LAG-3 blocking mAb, in combination with nivolumab (anti-PD1 mAb) has demonstrated efficacy in vitro and in vivo and is currently being evaluated in clinical trials in different hematological malignancies, including CLL (NCT02061761) [35].